Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma

We assessed the safety, efficacy, maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D) of selinexor, a first in class oral selective inhibitor of nuclear export (100 mg once weekly [QW] or 60 mg twice weekly), in combination with daratumumab (16 mg/kg per label) and dexamethasone (4...

Descripción completa

Detalles Bibliográficos
Autores principales: Gasparetto, Cristina, Lentzsch, Suzanne, Schiller, Gary, Callander, Natalie, Tuchman, Sascha, Chen, Christine, White, Darrell, Kotb, Rami, Sutherland, Heather, Sebag, Michael, Baljevic, Muhamed, Bensinger, William, LeBlanc, Richard, Venner, Chris, Bahlis, Nizar, Rossi, Adriana, Biran, Noa, Sheehan, Heidi, Saint‐Martin, Jean‐Richard, Van Domelen, Dane, Kai, Kazuharu, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Lipe, Brea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematologic Malignancy–Plasma Cell
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176052/
https://www.ncbi.nlm.nih.gov/pubmed/35846104
http://dx.doi.org/10.1002/jha2.122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176052/
https://www.ncbi.nlm.nih.gov/pubmed/35846104
http://dx.doi.org/10.1002/jha2.122

Ejemplares similares